TETRALOGIC PHARMACEUTICALS CORP: 10-Q filed 2014-08-05

Name: TETRALOGIC PHARMACEUTICALS CORP: 10-Q filed 2014-08-05
Creator: TETRALOGIC PHARMACEUTICALS CORP

What TETRALOGIC PHARMACEUTICALS CORP reported in its quarterly report filed 2014-08-05 (fiscal Q2 2014): 30 published measures, 84 facts as tagged in accession 0001104659-14-056869.

This filing

Form: 10-Q (quarterly report)
Filed: 2014-08-05
Fiscal period: fiscal Q2 2014
Accession: 0001104659-14-056869 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TETRALOGIC PHARMACEUTICALS CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-06-30	128,224,214	USD
At 2013-12-31	55,502,421	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-06-30	75,338,167	USD
At 2013-12-31	4,953,368	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2014-06-30	52,886,047	USD
At 2013-12-31	50,549,053	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-06-30	40,242,102	USD
At 2013-12-31	55,135,508	USD
At 2013-06-30	6,020,383	USD
At 2012-12-31	4,511,889	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-9,354,438	USD	91
2014-01-01 to 2014-06-30	-14,688,505	USD	181
2013-04-01 to 2013-06-30	-3,892,149	USD	91
2013-01-01 to 2013-06-30	-7,320,821	USD	181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	376,165	USD	181
2013-01-01 to 2013-06-30	18,460	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-06-30	-104,560,743	USD
At 2013-12-31	-89,872,238	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	22,286,581	shares	91
2014-01-01 to 2014-06-30	22,266,556	shares	181
2013-04-01 to 2013-06-30	1,155,163	shares	91
2013-01-01 to 2013-06-30	1,127,628	shares	181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	22,350,657	shares	91
2014-01-01 to 2014-06-30	22,333,382	shares	181
2013-04-01 to 2013-06-30	1,155,163	shares	91
2013-01-01 to 2013-06-30	1,127,628	shares	181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-0.42	USD/shares	91
2014-01-01 to 2014-06-30	-0.66	USD/shares	181
2013-04-01 to 2013-06-30	-4.11	USD/shares	91
2013-01-01 to 2013-06-30	-8.01	USD/shares	181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-0.42	USD/shares	91
2014-01-01 to 2014-06-30	-0.67	USD/shares	181
2013-04-01 to 2013-06-30	-4.11	USD/shares	91
2013-01-01 to 2013-06-30	-8.01	USD/shares	181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-06-30	466,395	USD
At 2013-12-31	139,577	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2014-01-01 to 2014-06-30	1,642,132	USD	181
2013-01-01 to 2013-06-30	205,897	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-8,787,101	USD	91
2014-01-01 to 2014-06-30	-14,418,135	USD	181
2013-04-01 to 2013-06-30	-3,042,699	USD	91
2013-01-01 to 2013-06-30	-6,264,081	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-06-30	72,401,876	USD
At 2013-12-31	55,308,718	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	139,446	USD	91
2014-01-01 to 2014-06-30	139,446	USD	181
2013-04-01 to 2013-06-30	905,946	USD	91
2013-01-01 to 2013-06-30	1,113,241	USD	181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-06-30	6,127,782	USD
At 2013-12-31	4,930,400	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2014-06-30	1,774,182	USD
At 2013-12-31	1,215,198	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2014-06-30	14,326,396	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	8,787,101	USD	91
2014-01-01 to 2014-06-30	14,418,135	USD	181
2013-04-01 to 2013-06-30	3,042,699	USD	91
2013-01-01 to 2013-06-30	6,264,081	USD	181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	4,864,189	USD	91
2014-01-01 to 2014-06-30	7,986,938	USD	181
2013-04-01 to 2013-06-30	2,047,053	USD	91
2013-01-01 to 2013-06-30	4,290,517	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-06-30	22,307,138	shares
At 2013-12-31	22,199,256	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-06-30	157,443,941	USD
At 2013-12-31	140,419,071	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2014-06-30	35,230,516	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2014-06-30	1,277,480	USD
At 2013-12-31	54,126	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2014-06-30	3,926,456	USD
At 2013-12-31	2,921,458	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2014-06-30	2,025,358	USD
At 2013-12-31	153,210	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-9,353,504	USD	91
2014-01-01 to 2014-06-30	-14,687,887	USD	181
2013-04-01 to 2013-06-30	-3,892,149	USD	91
2013-01-01 to 2013-06-30	-7,320,821	USD	181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	-9,354,438	USD	91
2014-01-01 to 2014-06-30	-14,688,505	USD	181
2013-04-01 to 2013-06-30	-4,753,137	USD	91
2013-01-01 to 2013-06-30	-9,033,335	USD	181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-04-01 to 2014-06-30	3,004,912	USD	91
2014-01-01 to 2014-06-30	5,513,197	USD	181
2013-04-01 to 2013-06-30	995,646	USD	91
2013-01-01 to 2013-06-30	1,973,564	USD	181

Inspect the source

Entity: TETRALOGIC PHARMACEUTICALS CORP / CIK 0001361248
Captured: 2026-09-23 02:51 UTC
SEC response SHA-256: 459ce70c5176daae13423155d739231f692bd0099616e958546766a485307349

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001361248.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))